SLS - CIK 0001390478
The table below shows SELLAS Life Sciences Group, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.85M | -$9.07M | -$10.76M | -$12.13M | -$7.15M | -$10.27M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
SELLAS Life Sciences Group, Inc. reported operating cash flow of -$28.39M for fiscal year 2025. That is up 19.8% from -$35.40M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$11.85M (FY 2016) to -$28.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $44.15M | $23.58M | $26.65M | $18.90M | $47.00K | $3.00M |